Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Thu Ho

Pediatric Endocrinology San Jose, CA Medical Doctor

NPI 1245437433 CMS profile 854052

2690 S White Rd Ste 50, # S672d, San Jose, CA 95148

Open in the dashboard

General payments

$5,412

237 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Thu Ho of San Jose, CA is reported in the CMS Open Payments database as having received $5,412 across 237 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 76th percentile of Pediatric Endocrinology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,146 37
2024 General $912 43
2023 General $1,182 49
2022 General $904 49
2021 General $699 30
2020 General $327 15
2019 General $243 14

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Thu Ho
  • Pediatric Endocrinology median
  • Middle half of Pediatric Endocrinology
  • National median

In program year 2025, general payments to Thu Ho were reported at $1,146. Among 971 Pediatric Endocrinology profiles paid that year, the median was $293 and the middle half received between $106 and $1,640.

Show as a table
Year Thu Ho Pediatric Endocrinology median Middle half National median
2019 $243 $196 $68–$845 $163
2020 $327 $124 $37–$722 $114
2021 $699 $134 $35–$691 $132
2022 $904 $177 $47–$726 $149
2023 $1,182 $236 $75–$887 $160
2024 $912 $259 $91–$979 $164
2025 $1,146 $293 $106–$1,640 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $681 51 payments
  2. Novo Nordisk Inc $553 18 payments
  3. Xeris Pharmaceuticals, Inc. $537 29 payments
  4. IBSA Pharma Inc. $528 15 payments
  5. Sanofi-Aventis U.S. LLC $472 13 payments
  6. Amgen Inc. $379 18 payments
  7. Lilly USA, LLC $341 13 payments
  8. AstraZeneca Pharmaceuticals LP $217 7 payments
  9. AbbVie, Inc. $195 11 payments
  10. Abbott Laboratories $183 9 payments
  11. Other $1,326 53 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,370 236 payments
  2. Education $42 1 payment
Products named General payments · program years 2019–2025
  1. BENLYSTA $681 51 payments
  2. Tirosint $528 15 payments
  3. Ozempic $503 16 payments
  4. TZIELD $370 7 payments
  5. GVOKE PFS $299 16 payments
  6. Licart $257 12 payments
  7. RYBELSUS $253 14 payments
  8. GVOKE HYPOPEN $221 12 payments
  9. Enbrel $203 9 payments
  10. AFREZZA $182 5 payments
  11. Other $2,911 137 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

237 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Endocrinology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record